Literature DB >> 24042017

Myocardial energy shortage and unmet anaplerotic needs in the fasted long-chain acyl-CoA dehydrogenase knockout mouse.

Adrianus J Bakermans1, Michael S Dodd, Klaas Nicolay, Jeanine J Prompers, Damian J Tyler, Sander M Houten.   

Abstract

AIMS: The aim of this animal study is to assess fasting-induced changes in myocardial substrate metabolism and energy status as a consequence of mitochondrial long-chain fatty acid β-oxidation deficiency, using magnetic resonance spectroscopy (MRS). METHODS AND
RESULTS: Carbon-13 ((13)C) MRS of hyperpolarized [1-(13)C]pyruvate was used to assess in vivo pyruvate dehydrogenase (PDH) activity in fed and fasted wild-type (WT) mice and long-chain acyl-CoA dehydrogenase knockout (LCAD KO) mice. PDH activity decreased after fasting in both genotypes, but was 2.7-fold higher in fasted LCAD KO mice compared with fasted WT mice. Incorporation of the (13)C label into the myocardial malate and aspartate pools in fasted LCAD KO mice demonstrates enhanced activity of anaplerotic pathways in fasted LCAD KO hearts. These findings were corroborated by ex vivo assays revealing partially depleted pools of citric acid cycle intermediates in fasted LCAD KO myocardium, suggesting an increased, but unmet need for anaplerosis. The in vivo myocardial energy status, assessed using phosphorous-31 ((31)P) MRS, was lower in fasted LCAD KO mice than in fasted WT mice.
CONCLUSION: This study revealed that the heart of fasted LCAD KO mice has an elevated reliance on glucose oxidation, in combination with an unmet demand for myocardial anaplerosis. Due to a lack of substrate availability, the sustained myocardial glucose uptake and PDH activity in LCAD KO mice are ineffective to maintain metabolic homeostasis during fasting, which is reflected by an impaired myocardial energy status in fasted LCAD KO mice.

Entities:  

Keywords:  Carbon-13 magnetic resonance spectroscopy; Inborn errors of metabolism; MRI; Mouse model; Phosphorous-31 magnetic resonance spectroscopy

Mesh:

Substances:

Year:  2013        PMID: 24042017     DOI: 10.1093/cvr/cvt212

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  16 in total

1.  Unique plasma metabolomic signatures of individuals with inherited disorders of long-chain fatty acid oxidation.

Authors:  Colin S McCoin; Brian D Piccolo; Trina A Knotts; Dietrich Matern; Jerry Vockley; Melanie B Gillingham; Sean H Adams
Journal:  J Inherit Metab Dis       Date:  2016-02-23       Impact factor: 4.982

2.  Slc22a5 haploinsufficiency does not aggravate the phenotype of the long-chain acyl-CoA dehydrogenase KO mouse.

Authors:  Pablo Ranea-Robles; Chunli Yu; Naomi van Vlies; Frédéric M Vaz; Sander M Houten
Journal:  J Inherit Metab Dis       Date:  2019-12-23       Impact factor: 4.982

Review 3.  Very long-chain acyl-CoA dehydrogenase (VLCAD-) deficiency-studies on treatment effects and long-term outcomes in mouse models.

Authors:  Sara Tucci
Journal:  J Inherit Metab Dis       Date:  2017-02-28       Impact factor: 4.982

4.  Acetylation of mitochondrial proteins by GCN5L1 promotes enhanced fatty acid oxidation in the heart.

Authors:  Dharendra Thapa; Manling Zhang; Janet R Manning; Danielle A Guimarães; Michael W Stoner; Robert M O'Doherty; Sruti Shiva; Iain Scott
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-05-19       Impact factor: 4.733

5.  Triheptanoin treatment in patients with pediatric cardiomyopathy associated with long chain-fatty acid oxidation disorders.

Authors:  J Vockley; J Charrow; J Ganesh; M Eswara; G A Diaz; E McCracken; R Conway; G M Enns; J Starr; R Wang; J E Abdenur; J Sanchez-de-Toledo; D L Marsden
Journal:  Mol Genet Metab       Date:  2016-08-27       Impact factor: 4.797

6.  In vivo mouse myocardial (31)P MRS using three-dimensional image-selected in vivo spectroscopy (3D ISIS): technical considerations and biochemical validations.

Authors:  Adrianus J Bakermans; Desiree Abdurrachim; Bastiaan J van Nierop; Anneke Koeman; Inge van der Kroon; Antonius Baartscheer; Cees A Schumacher; Gustav J Strijkers; Sander M Houten; Coert J Zuurbier; Klaas Nicolay; Jeanine J Prompers
Journal:  NMR Biomed       Date:  2015-08-13       Impact factor: 4.044

7.  Anaplerotic treatment of long-chain fat oxidation disorders with triheptanoin: Review of 15 years Experience.

Authors:  Charles R Roe; Henri Brunengraber
Journal:  Mol Genet Metab       Date:  2015-10-24       Impact factor: 4.797

8.  The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome.

Authors:  Yan Huang; Corey Powers; Victoria Moore; Caitlin Schafer; Mindong Ren; Colin K L Phoon; Jeanne F James; Alexander V Glukhov; Sabzali Javadov; Frédéric M Vaz; John L Jefferies; Arnold W Strauss; Zaza Khuchua
Journal:  Orphanet J Rare Dis       Date:  2017-03-09       Impact factor: 4.123

Review 9.  Mitochondrial dysfunction in fatty acid oxidation disorders: insights from human and animal studies.

Authors:  Moacir Wajner; Alexandre Umpierrez Amaral
Journal:  Biosci Rep       Date:  2015-11-20       Impact factor: 3.840

10.  The von Hippel-Lindau Chuvash mutation in mice alters cardiac substrate and high-energy phosphate metabolism.

Authors:  Mary Slingo; Mark Cole; Carolyn Carr; Mary K Curtis; Michael Dodd; Lucia Giles; Lisa C Heather; Damian Tyler; Kieran Clarke; Peter A Robbins
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-07-15       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.